ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0726

Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care
Abstract Number: 0006

Oral Administration of a Novel Pyrrolopyrimidine Derivative That Inhibits BAFF Signaling Suppresses B Cell Differentiation and Production of Autoantibody in Autoimmune Model Mice
Abstract Number: 1689

Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
Abstract Number: 0325

Ordering Practices and Diagnostic Utility of Cardiac MRI in SLE Patients at a Single Academic Institution
Abstract Number: 1891

Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab: A Randomized Placebo-Controlled Trial
Abstract Number: 1661

Osteoclastogenesis and Vascular Endothelial Growth Factor Blood Levels in Patients with Systemic Sclerosis with and Without Calcinosis Cutis
Abstract Number: 0574

Osteoporosis in Elderly Men; An Underestimated and Underdiagnosed Morbid Entity
Abstract Number: 0437

Outcome Measures in Patients with Neurologic Involvement in ANCA-associated Vasculitis: Data from Multicenter Longitudinal Observational Study
Abstract Number: 1872

Outcome of Idiopathic Inflammatory Myositis Patients Who Received Rituximab: A Single Centre Retrospective Study
Abstract Number: 2022

Outcome of Pregnancy in Women with Primary Sjögren’s Syndrome Compared to the General Population: The French Multicenter Prospective GR2 Study
Abstract Number: 0854

Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
Abstract Number: 1566

Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study
Abstract Number: 1929

Outcomes and Safety of Anakinra for the Treatment of Multisystem Inflammatory Syndrome in Children
Abstract Number: 1420

Outcomes in Patients with Rheumatoid Arthritis Initiating Monotherapy with Etanercept, Adalimumab, or Janus Kinase Inhibitors
Abstract Number: 0679

Outcomes of Antiphospholipid Antibody Syndrome and Acute Coronary Syndrome: Analysis of National Inpatient Sample

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].